Cerliponase alfa · BRINEURA

Protein / enzyme therapeutic

Approvedregulatory verdict

Evidence outlook

Approved: Neuronal Ceroid Lipofuscinosis Type 2

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signalSingle-arm, accepted for approval (FDA label)

Also approved (2)
JP
  • Treatment of neuronal ceroid lipofuscinosis type 2 (CLN2)
Product first approved 2019PMDA
EU
  • Neuronal ceroid lipofuscinosis type 2 (CLN2) disease
Product first approved 2017EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Neuronal Ceroid Lipofuscinosis Type 2
Phase 1/2 (3)
Neuronal Ceroid Lipofuscinosis Type 2
NCT05152914 · David L Rogers, MD
2021-11-01 – 2027-03-06 · Neuronal Ceroid Lipofuscinosis Type 2
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.